2025
CD19 Directed CAR T Therapy for Transformed Follicular Lymphoma: A CIBMTR Analysis
Thiruvengadam S, Ahn K, Patel J, Lian Q, Hertzberg M, Epperla N, Metheny L, Hong S, Jain T, Aljurf M, Beitinjaneh A, Vaughn J, Gopal A, Iqbal M, Wirk B, Manjappa S, Oliver C, Mohty R, Shadman M, Turtle C, Hamadani M, Herrera A. CD19 Directed CAR T Therapy for Transformed Follicular Lymphoma: A CIBMTR Analysis. American Journal Of Hematology 2025, 100: 1803-1812. PMID: 40762207, DOI: 10.1002/ajh.70027.Peer-Reviewed Original ResearchConceptsTransformed follicular lymphomaNon-relapse mortalityProgression-free survivalCAR-T infusionCAR-T therapyCytokine release syndromeCAR-TOverall survivalFollicular lymphomaT therapyCumulative incidenceCD19-directed chimeric antigen receptor T cellsCenter for International Blood and Marrow Transplant Research registryT infusionAssociated with inferior progression-free survivalChimeric antigen receptor T cellsCD19 CAR-T therapyCumulative incidence of relapseInferior progression-free survivalRisk of non-relapse mortalityAssociated with chemotherapy resistanceMedian prior linesCD19-CAR-TIncidence of relapseAxicabtagene ciloleucel
2023
Brentuximab vedotin plus AVD for Hodgkin lymphoma: incidence and management of peripheral neuropathy in a multisite cohort
Bowers J, Anna J, Bair S, Annunzio K, Epperla N, Pullukkara J, Gaballa S, Spinner M, Li S, Messmer M, Nguyen J, Ayers E, Wagner C, Hu B, Di M, Huntington S, Furqan F, Shah N, Chen C, Ballard H, Hughes M, Chong E, Nasta S, Barta S, Landsburg D, Svoboda J. Brentuximab vedotin plus AVD for Hodgkin lymphoma: incidence and management of peripheral neuropathy in a multisite cohort. Blood Advances 2023, 7: 6630-6638. PMID: 37595053, PMCID: PMC10628810, DOI: 10.1182/bloodadvances.2023010622.Peer-Reviewed Original ResearchConceptsProgression-free survivalClassical Hodgkin lymphomaPeripheral neuropathyNontrial settingHodgkin's lymphomaTwo-year progression-free survivalTreatment-limiting side effectsInferior progression-free survivalECHELON-1 trialExperienced grade 1Multisite retrospective studyAdvanced-stage patientsDiscontinuation ratesOverall survivalPerformance statusFrontline treatmentRetrospective studyClinical trialsMultisite cohortIneligibility criteriaDose reductionHigh incidenceSide effectsPatientsGrade 1Impact of Second Primary Malignancy Post-Autologous Transplantation on Outcomes of Multiple Myeloma: A CIBMTR Analysis
Ragon B, Shah M, D’Souza A, Estrada-Merly N, Gowda L, George G, de Lima M, Hashmi S, Kharfan-Dabaja M, Majhail N, Banerjee R, Saad A, Hildebrandt G, Mian H, Abid M, Battiwalla M, Lekakis L, Patel S, Murthy H, Nieto Y, Strouse C, Badawy S, Al Hadidi S, Dholaria B, Aljurf M, Vesole D, Lee C, Pawarode A, Gergis U, Miller K, Holmberg L, Afrough A, Solh M, Munshi P, Nishihori T, Anderson L, Wirk B, Kaur G, Qazilbash M, Shah N, Kumar S, Usmani S. Impact of Second Primary Malignancy Post-Autologous Transplantation on Outcomes of Multiple Myeloma: A CIBMTR Analysis. Blood Advances 2023, 7: 2746-2757. PMID: 36827681, PMCID: PMC10275699, DOI: 10.1182/bloodadvances.2022009138.Peer-Reviewed Original ResearchConceptsSecond hematological malignanciesSecond primary malignanciesProgression-free survivalMultiple myelomaOverall survivalMaintenance therapyDevelopment of SPMsRisk of SPMAutologous hematopoietic stem cell transplantationInferior progression-free survivalHematopoietic stem cell transplantationHigh-dose melphalanMelphalan conditioning regimenSubsequent maintenance therapyStem cell transplantationFrequent primary causeCIBMTR analysisLenalidomide maintenanceAuto-HSCTConditioning regimenMedian survivalPrimary malignancyAdult patientsCell transplantationClinical trialsBrentuximab vedotin + AVD for newly diagnosed classic Hodgkin lymphoma (cHL): Incidence and management of peripheral neuropathy in a multi-institution cohort.
Bowers J, Anna J, Bair S, Annunzio K, Epperla N, Joy Pullukkara J, Gaballa S, Spinner M, Li S, Messmer M, Nguyen J, Ayers E, Wagner C, Hu B, Di M, Huntington S, Furqan F, Shah N, Chen C, Svoboda J. Brentuximab vedotin + AVD for newly diagnosed classic Hodgkin lymphoma (cHL): Incidence and management of peripheral neuropathy in a multi-institution cohort. Journal Of Clinical Oncology 2023, 41: 7542-7542. DOI: 10.1200/jco.2023.41.16_suppl.7542.Peer-Reviewed Original ResearchProgression-free survivalClassic Hodgkin lymphomaECHELON-1 trialBrentuximab vedotinPeripheral neuropathyNon-trial settingOverall survivalLast followInferior progression-free survivalCox proportional hazards modelExperienced grade 1Grade peripheral neuropathyMulti-institution cohortEffect of discontinuationKaplan-Meier methodAdvanced-stage patientsMultivariable logistic regressionProportional hazards modelHigher initial doseDose holdsCommon toxicitiesMedian followDiscontinuation ratesPerformance statusMedian ageEfficacy of Osimertinib in Patients with Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion Mutations
Grant M, Aredo J, Starrett J, Stockhammer P, van Rosenburgh I, Wurtz A, Piper-Valillo A, Piotrowska Z, Falcon C, Yu H, Aggarwal C, Scholes D, Patil T, Nguyen C, Phadke M, Li F, Neal J, Lemmon M, Walther Z, Politi K, Goldberg S. Efficacy of Osimertinib in Patients with Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion Mutations. Clinical Cancer Research 2023, 29: of1-of8. PMID: 36913537, PMCID: PMC10493186, DOI: 10.1158/1078-0432.ccr-22-3497.Peer-Reviewed Original ResearchConceptsProgression-free survivalNon-small cell lung cancerInferior progression-free survivalMulticenter retrospective cohortEfficacy of osimertinibMulti-institutional cohortCell lung cancerExon 19 deletion mutationUncommon EGFRRetrospective cohortClinical outcomesClinical efficacyLung cancerOsimertinib efficacyEGFR mutationsPreclinical modelsEx19delPatientsAACR Genie databaseLater linesOsimertinibMutant cohortFirst lineCohortEfficacyInterim Positron Emission Tomography During Frontline Chemoimmunotherapy for Follicular Lymphoma
Merryman R, Michaud L, Redd R, Mondello P, Park H, Spilberg G, Robertson M, Taranto E, Ahmed G, Chase M, Jeter E, Ahn I, Brown J, Crombie J, Davids M, Fisher D, Jacobsen E, Jacobson C, Kim A, LaCasce A, Ng S, Odejide O, Parry E, Salles G, Zelenetz A, Armand P, Schöder H, Jacene H. Interim Positron Emission Tomography During Frontline Chemoimmunotherapy for Follicular Lymphoma. HemaSphere 2023, 7: e826. PMID: 36713355, PMCID: PMC9875968, DOI: 10.1097/hs9.0000000000000826.Peer-Reviewed Original ResearchInterim positron emission tomographyProgression-free survivalPositron emission tomographyDeauville scoreFollicular lymphomaFrontline chemoimmunotherapyMultivariable analysisSignificant predictorsResponse-adapted treatment strategiesTreatment positron emission tomographyInferior progression-free survivalEmission tomographyMaximum standardized uptake valueHigh-grade follicular lymphomaHigh-risk patientsSubset of patientsStandardized uptake valueProgression of diseaseMost patientsIndependent predictorsExcellent outcomesEarly progressionTreatment strategiesEarly predictorSeparate cohort
2022
Genomic and Clinical Prognostic Factors in Patients With Advanced Urothelial Carcinoma Receiving Immune Checkpoint Inhibitors
Chawla N, Sayegh N, Tripathi N, Govindarajan A, Zengin Z, Phillip E, Dizman N, Meza L, Muddasani R, Chehrazi-Raffle A, Malhotra J, Hsu J, Agarwal N, Pal S, Tripathi A. Genomic and Clinical Prognostic Factors in Patients With Advanced Urothelial Carcinoma Receiving Immune Checkpoint Inhibitors. Clinical Genitourinary Cancer 2022, 21: 69-75. PMID: 36509613, DOI: 10.1016/j.clgc.2022.11.007.Peer-Reviewed Original ResearchConceptsProgression-free survivalOverall response rateTumor mutational burdenOverall survivalWorse OSPrimary diseaseMultivariate analysisMedian progression-free survivalImmune checkpoint inhibitor therapyInferior progression-free survivalPromoter mutationsWorse progression-free survivalCheckpoint inhibitor therapyMedian overall survivalImmune checkpoint inhibitorsTertiary cancer centerClinical prognostic factorsPrimary tumor siteTERT promoter mutationsCheckpoint inhibitorsInhibitor therapyLaboratory parametersPrognostic factorsCancer CenterFemale sex
2020
Serial Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line Chemotherapy
Magbanua MJM, Hendrix LH, Hyslop T, Barry WT, Winer EP, Hudis C, Toppmeyer D, Carey LA, Partridge AH, Pierga JY, Fehm T, Vidal-Martínez J, Mavroudis D, Garcia-Saenz JA, Stebbing J, Gazzaniga P, Manso L, Zamarchi R, Antelo ML, De Mattos-Arruda L, Generali D, Caldas C, Munzone E, Dirix L, Delson AL, Burstein HJ, Qadir M, Ma C, Scott JH, Bidard FC, Park JW, Rugo HS. Serial Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line Chemotherapy. Journal Of The National Cancer Institute 2020, 113: 443-452. PMID: 32770247, PMCID: PMC8023821, DOI: 10.1093/jnci/djaa113.Peer-Reviewed Original ResearchConceptsProgression-free survivalFirst-line chemotherapyOverall survivalBaseline CTCsCTC statusPrognostic groupsInferior progression-free survivalMetastatic breast cancer patientsFuture prospective clinical trialsNovel prognostic groupsMetastatic breast cancerProspective clinical trialsRisk stratification strategiesBreast cancer patientsCourse of treatmentMore effective treatmentsUndetectable CTCsMBC patientsHazard ratioPoor outcomePrognostic significanceCox regressionCancer patientsClinical trialsCTC measurement
2015
Differences in Outcome of Patients with Syncytial Variant Hodgkin Lymphoma (HL) Compared with Typical Nodular Sclerosis HL
Sethi T, Nguyen V, Li S, Morgan D, Greer J, Reddy N. Differences in Outcome of Patients with Syncytial Variant Hodgkin Lymphoma (HL) Compared with Typical Nodular Sclerosis HL. Blood 2015, 126: 1441. DOI: 10.1182/blood.v126.23.1441.1441.Peer-Reviewed Original ResearchNodular sclerosis Hodgkin lymphomaProgression-free survivalOutcomes of patientsAdvanced stage diseaseOverall survivalComplete responseHodgkin's lymphomaB symptomsStage diseaseSV groupAchievement of CRInferior progression-free survivalMedian progression-free survivalHodgkin/Reed-Sternberg cellsInstitutional IRB approvalMedian overall survivalStandard ABVD chemotherapyStandard salvage regimensHigh-dose therapyKaplan-Meier methodOnly independent predictorStem cell transplantStage of diseaseCompletion of treatmentNew immunomodulatory agents
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply